Etifoxine

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Retrieved on: 
Friday, March 24, 2023
Consensus, Cognition, Acceleration, GABA, Etifoxine, MCCB, Quantitative electroencephalography, Benzodiazepine, Anxiety, COMP, Brain, COMPASS, Patient, Standard of care, CIAS, Pivotal, Entrepreneurship, TRD, Mental health, Nursing, Vaccine, Pharmaceutical industry, Medical imaging

Notably, in four clinical studies that assessed cognition, including one in patients with CIAS, the compound consistently demonstrated pro-cognitive effects.

Key Points: 
  • Notably, in four clinical studies that assessed cognition, including one in patients with CIAS, the compound consistently demonstrated pro-cognitive effects.
  • More details of the phase 2 clinical development plan will be provided upon initiation of the study.
  • In January 2022, positive results were announced from the phase 1 single and multiple ascending dose study of GRX-917.
  • In the fourth quarter of 2022, the first subject was dosed in a Phase 1 study of VLS-01.

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

Retrieved on: 
Monday, March 6, 2023
Consensus, Standard of care, Cognition, Ketamine, Etifoxine, Brain, Lorazepam, Alprazolam, COMP, CIAS, Anxiety disorder, Partnership, Patient, NMDA, Anxiety, COMPASS, Quantitative electroencephalography, Benzodiazepine, Pivotal, Acceleration, Entrepreneurship, Perception, Safety, Consensus decision-making, GABA, Pharmaceutical industry, Nursing, Medical imaging, Neuroscience

“Along these lines, we are excited to announce the updated clinical strategy for GRX-917.

Key Points: 
  • “Along these lines, we are excited to announce the updated clinical strategy for GRX-917.
  • Notably, in four clinical studies that assessed cognition, including one in patients with CIAS, the compound consistently demonstrated pro-cognitive effects.
  • The clinical development plan has been updated to now proceed with a phase 2 study in patients.
  • As part of a strategic review of its pipeline and to enhance operational efficiency and focus, the Company has reduced its workforce by approximately 30%.